Published in AAPS J on March 23, 2011
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. Lipids Health Dis (2011) 0.81
A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. Br J Pharmacol (2014) 0.80
Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug: formulation and pharmacokinetic evaluation. Int J Nanomedicine (2015) 0.79
Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112. Int J Nanomedicine (2015) 0.76
A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res (1995) 12.09
Physiological parameters in laboratory animals and humans. Pharm Res (1993) 8.14
Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis (2007) 4.87
Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health (1997) 3.48
Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother (1978) 2.79
Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol (2011) 2.18
The world's most neglected diseases. BMJ (2002) 2.15
Quantitative Relations in the Physiological Constitutions of Mammals. Science (1949) 2.04
Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol (2008) 1.88
Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci (1983) 1.85
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother (2002) 1.79
Distribution and activity of amphotericin B in humans. J Infect Dis (1985) 1.77
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother (2002) 1.61
Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother (1991) 1.39
Amphotericin B. Appl Microbiol Biotechnol (2005) 1.28
Susceptibilities of macrophage populations to infection in vitro by Leishmania donovani. Infect Immun (1987) 1.16
Is there a correlation between serum antifungal drug concentration and clinical outcome? J Infect (1994) 1.15
Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm (2003) 1.12
Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm (2009) 1.10
Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother (1989) 1.07
Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother (2009) 1.07
Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother (2002) 0.94
Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125. J Pharmacokinet Biopharm (1994) 0.89
Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling. Pharm Res (1998) 0.88
Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats. Pharm Res (1995) 0.86
Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target (2007) 0.84
Pharmacokinetics of amphotericin B in rats as a function of dose following constant-rate intravenous infusion. Biopharm Drug Dispos (1995) 0.82
Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J Pharm Pharmacol (1997) 0.81
Pharmacokinetic and biodistribution studies of amphotericin B microspheres. J Microencapsul (2009) 0.78
Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential. Arzneimittelforschung (2009) 0.78
Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. J Antimicrob Chemother (2009) 0.78
Initial and long-term efficacy of a lipid emulsion of amphotericin B desoxycholate in the management of canine leishmaniasis. J Vet Intern Med (2003) 0.78
Disposition kinetics of amphotericin B in rats. The influence of dose. Drug Metab Dispos (1992) 0.77
A drug burden index to define the functional burden of medications in older people. Arch Intern Med (2007) 2.84
Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care (2010) 1.60
Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate (2010) 1.59
Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos (2004) 1.56
Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm Res (2008) 1.54
Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm Res (2004) 1.47
Merging systems biology with pharmacodynamics. Sci Transl Med (2012) 1.39
Which new approaches to tackling neglected tropical diseases show promise? PLoS Med (2010) 1.34
Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn (2009) 1.33
Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J Pharm Sci (2008) 1.21
Drug burden index score and functional decline in older people. Am J Med (2009) 1.19
Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis (2009) 1.13
Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Dev Ind Pharm (2007) 1.11
Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm (2009) 1.10
Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother (2009) 1.07
Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol (2012) 1.06
Pharmacodynamic profiles of ketamine (R)- and (S)- with 5-day inpatient infusion for the treatment of complex regional pain syndrome. Pain Physician (2010) 1.05
Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther (2008) 1.05
Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats. Pharm Res (2011) 1.04
Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition. AAPS J (2007) 1.03
Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci (2007) 1.02
Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake. Adv Drug Deliv Rev (2004) 1.02
Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res (2010) 1.01
Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res (2005) 1.01
Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats. Antimicrob Agents Chemother (2003) 1.00
Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci (2007) 0.99
Pharmacokinetics of recombinant human leukemia inhibitory factor in sheep. J Pharmacol Exp Ther (2004) 0.96
Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans. J Pharmacol Exp Ther (2009) 0.96
Effects of protein calorie malnutrition on the pharmacokinetics of ketamine in rats. Drug Metab Dispos (2004) 0.95
Knockdown of scavenger receptor class B type I reduces prostate specific antigen secretion and viability of prostate cancer cells. Prostate (2011) 0.95
Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm Res (2005) 0.94
Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects. J Clin Invest (2013) 0.94
Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother (2004) 0.93
A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model. PLoS Negl Trop Dis (2010) 0.92
The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm (2007) 0.92
Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant (2013) 0.92
Methotrexate loaded poly(L-lactic acid) microspheres for intra-articular delivery of methotrexate to the joint. J Pharm Sci (2004) 0.91
Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice. Metabolism (2003) 0.91
Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J Pharmacokinet Pharmacodyn (2009) 0.91
Arachidonic acid activation of intratumoral steroid synthesis during prostate cancer progression to castration resistance. Prostate (2010) 0.91
The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis. Expert Opin Drug Deliv (2009) 0.91
Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. AAPS J (2009) 0.90
Cholesterol as a potential target for castration-resistant prostate cancer. Pharm Res (2010) 0.90
Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol (2009) 0.89
In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles. Eur J Pharm Biopharm (2008) 0.89
Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. Cancer Res (2012) 0.89
Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma. Lipids Health Dis (2009) 0.89
Interspecies modeling and prediction of human exenatide pharmacokinetics. Pharm Res (2012) 0.89
Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome. Chirality (2010) 0.88
Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT). Prostate (2008) 0.88
Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation. Pharm Res (2012) 0.87
Pharmacokinetics and biodistribution of N-isopropylacrylamide copolymers for the design of pH-sensitive liposomes. Biomaterials (2009) 0.87
Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. Adv Drug Deliv Rev (2007) 0.87
A review of the application of lipid-based systems in systemic, dermal/ transdermal, and ocular drug delivery. Crit Rev Ther Drug Carrier Syst (2008) 0.87
Effects of monoglycerides on P-glycoprotein: modulation of the activity and expression in Caco-2 cell monolayers. Mol Pharm (2008) 0.87
Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol (2008) 0.86
A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. J Clin Pharmacol (2011) 0.86
Influence of phytostanol phosphoryl ascorbate, FM-VP4, on pancreatic lipase activity and cholesterol accumulation within Caco-2 cells. J Pharm Pharm Sci (2002) 0.86
Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein deficient mice: implications for cholesterol metabolism. Lipids Health Dis (2008) 0.85
Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells. J Pharm Pharm Sci (2007) 0.85
Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. Drug Dev Ind Pharm (2004) 0.85
Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. J Pharm Sci (2004) 0.85
Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci (2003) 0.85
Disodium Ascorbyl Phytostanyl Phosphates (FM-VP4) reduces plasma cholesterol concentration, body weight and abdominal fat gain within a dietary-induced obese mouse model. J Pharm Pharm Sci (2005) 0.85
Poloxamer 407 (P-407)-mediated reduction in the gene expression of ATP-binding-cassette transporter A1 may contribute to increased cholesterol in peripheral tissues of P-407-treated rats. Eur J Pharmacol (2006) 0.85
Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects. Clin Pharmacokinet (2008) 0.84
Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]. J Pharmacol Exp Ther (2003) 0.84
Fluorescence of amphotericin B-deoxycholate (fungizone) monomers and aggregates and the effect of heat-treatment. Langmuir (2007) 0.84
Inhibition of intestinal absorption of cholesterol by surface-modified nanostructured aluminosilicate compounds. J Pharm Sci (2009) 0.83
Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci (2003) 0.83
Biodistribution and tissue toxicity of amphotericin B in mice following multiple dose administration of a novel oral lipid-based formulation (iCo-009). J Antimicrob Chemother (2010) 0.83
Long circulating lipid nanocapsules for drug detoxification. Biomaterials (2007) 0.83
Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharm Drug Dispos (2011) 0.83
Mechanisms of subcutaneous absorption of rituximab in rats. Drug Metab Dispos (2012) 0.83
Lipid-based systems for the enhanced delivery of poorly water soluble drugs. Adv Drug Deliv Rev (2007) 0.83
Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: modeling interoccasion pharmacodynamic variability. Pharm Res (2007) 0.82
Pharmacokinetic interactions between monoamine oxidase A inhibitor harmaline and 5-methoxy-N,N-dimethyltryptamine, and the impact of CYP2D6 status. Drug Metab Dispos (2013) 0.82
HPLC-atmospheric pressure chemical ionization mass spectrometric method for enantioselective determination of R,S-propranolol and R,S-hyoscyamine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.82
Development and characterization of liposomal disodium ascorbyl phytostanyl phosphates (FM-VP4). Drug Dev Ind Pharm (2004) 0.82
Barriers to treatment for visceral leishmaniasis in hyperendemic areas: India, Bangladesh, Nepal, Brazil and Sudan. Drug Dev Ind Pharm (2010) 0.82
Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis. J Clin Pharmacol (2008) 0.82
Identification of plasma membrane macro- and microdomains from wavelet analysis of FRET microscopy. Biophys J (2005) 0.82
Dual physiologically based pharmacokinetic model of liposomal and nonliposomal amphotericin B disposition. Pharm Res (2013) 0.81
The use of the United States FDA programs as a strategy to advance the development of drug products for neglected tropical diseases. Drug Dev Ind Pharm (2014) 0.81
Complete Apo AI deficiency in an Iraqi Mandaean family: case studies and review of the literature. J Clin Lipidol (2010) 0.81
Review of the quality of pediatric medications in developing countries. J Pharm Sci (2013) 0.81
Meta-analysis of nanoparticulate paclitaxel delivery system pharmacokinetics and model prediction of associated neutropenia. Pharm Res (2012) 0.81
Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. Lipids Health Dis (2011) 0.81
Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy. J Pharmacol Exp Ther (2012) 0.81
Quantitative structure-pharmacokinetic relationships. Expert Opin Drug Metab Toxicol (2010) 0.81
Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. Transplantation (2009) 0.81
Pharmacokinetics and toxicodynamics of pralidoxime effects on paraoxon-induced respiratory toxicity. Toxicol Sci (2010) 0.80
Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals. J Pharm Sci (2010) 0.80
Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis. Int J Pharm (2012) 0.80